phmacao net

phmacao net ZUG, Switzerland--(BUSINESS WIRE)--Dec 13, 2024-- Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024. 12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S. 2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patients and physicians. 13-16 Atopic dermatitis is also a highly heterogenous disease and can be associated with several comorbid conditions, namely mental health disorders and other autoimmune- or immune-mediated diseases. 2,13,17-19 For this reason, there remains a need for more novel, effective treatment options, as while currently available treatments for atopic dermatitis may improve some signs and symptoms, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree. 2,5-7 Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. 8 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis. 2,9-11 “As just one example of our innovative, science-based pipeline, Nemluvio is an important and effective new treatment option for patients with atopic dermatitis, where unmet needs remain. Another key milestone on Galderma’s journey, this FDA approval will accelerate the ongoing growth of our U.S. organization and our Therapeutic Dermatology Business, and underscores our commitment to delivering innovative first-in-class solutions to patients across the full spectrum of the fast-growing dermatology market.” FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of Nemluvio in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 years or older with moderate-to-severe atopic dermatitis. 20 Results demonstrated that patients treated with Nemluvio, administered subcutaneously every four weeks in combination with TCS, with or without TCI, showed statistically significant improvements on skin clearance in both co-primary endpoints. These were clearance (0) or almost-clearance (1) of skin lesions when assessed using the investigator’s global assessment (IGA) score, and achieving a 75% reduction in the Eczema Area and Severity Index (EASI) - when compared to placebo in combination with TCS, with or without TCI, after 16 weeks of treatment. 20 The trials also met all key secondary endpoints confirming significant responses on itch as early as Week 1, and statistically significant improvements in sleep disturbance with Nemluvio in combination with TCS, with or without TCI, when compared to placebo in combination with TCS, with or without TCI. 20 Overall, Nemluvio was well tolerated, and the safety profile was generally consistent between Nemluvio and placebo groups. 20 “Despite currently available treatment options, atopic dermatitis continues to have a massive impact worldwide, with patients not only burdened by intense itch and recurrent skin lesions, but also potentially several associated symptoms including sleep issues, pain, anxiety, and depression. I look forward to being able to offer this option to atopic dermatitis patients in my practice who are seeking relief from burdensome itch and lesions.” PROFESSOR JONATHAN SILVERBERG LEAD INVESTIGATOR OF THE ARCADIA CLINICAL PROGRAM, PROFESSOR OF DERMATOLOGY, GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES, UNITED STATES The FDA also approved Nemluvio as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024. 12 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion on December 12, 2024, recommending the approval of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo nodularis. 21 The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines in all 27 EU member states as well as Iceland, Liechtenstein, and Norway. Galderma also has marketing authorization applications for nemolizumab in both atopic dermatitis and prurigo nodularis under review by multiple additional regulatory authorities, including via the Access Consortium framework in countries such as Australia, Singapore, and Switzerland, as well as in Canada, Brazil, and South Korea. 22 Further submissions to other regulatory authorities will continue in 2025. As previously communicated, peak sales of nemolizumab are expected to reach more than 2 billion USD (expected beyond the 2023-2027 mid-term guidance period). Galderma anticipates nemolizumab to approach ‘blockbuster’ net sales run-rate by the end of 2027. Media can find more information about atopic dermatitis in this media toolkit . About Nemluvio ® (nemolizumab-ilto) Nemluvio ® (nemolizumab-ilto) was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan and Taiwan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 23,24 Important Safety Information Indications: NEMLUVIO ® (nemolizumab-ilto) is a prescription medicine used: to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age. to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age. Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO. Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you: are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO. are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: Breathing problems or wheezing Swelling of the face, lips, mouth, tongue, or throat Fainting, dizziness, feeling lightheaded Fast pulse Swollen lymph nodes Joint pain Fever Skin rash (red or rough skin) Nausea or vomiting General ill feeling Cramps in your stomach area The most common side effects of NEMLUVIO include: Eczema : headache, joint pain, hives (itchy red rash or wheals), and muscle aches Prurigo Nodularis: headache and skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches) These are not all of the possible side effects of NEMLUVIO. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800- FDA-1088. Please see full Prescribing Information including Patient Information. About the ARCADIA clinical trial program 20,25,26 The ARCADIA program included two identically designed, pivotal phase III clinical trials, which enrolled more than 1,700 patients – ARCADIA 1 and ARCADIA 2. These global, randomized, multicenter, double-blind, placebo-controlled phase III clinical trials, evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks compared to placebo (both administered with background topical corticosteroids with or without topical calcineurin inhibitors). The trials were conducted in adolescent and adult patients (12 years and over) with moderate-to-severe atopic dermatitis for an initial treatment phase of 16 weeks. Patients who responded to treatment (defined as patients who achieved an investigator’s global assessment score of clear (0) or almost clear (1), or a 75% or greater improvement in the eczema area and severity index score) were then re-randomized to a maintenance treatment phase for up to 48 weeks. About atopic dermatitis Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions. 1-3 It affects more than 230 million people worldwide and is the most common inflammatory skin disease, impacting almost four times more people than psoriasis. 2,27 While currently available treatments for atopic dermatitis show some improvements of signs and symptoms, not all patients experience itch relief and clear skin to the same degree, and many do not respond optimally to approved therapies. 2,5-7 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com . References: Yang G, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8): 2867. doi: https://doi.org/10.3390/ijms21082867 Langan SM, et al. Atopic dermatitis [published correction appears in Lancet. 2020;396(10253):758]. Lancet . 2020;396(10247):345-360. doi:10.1016/S0140- 6736(20)31286- 1 Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911 Silverberg JI, et al. Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Population-Based Study. J Invest Derm. 2015; 135, 56–66; doi:10.1038/jid.2014.325 Lobefaro F, et al. Atopic Dermatitis: Clinical Aspects and Unmet Needs. Biomedicines. 2022;10:2927. doi:10.3390/biomedicines10112927 Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12): 1053-1101. doi:10.1111/1346-8138.15090 Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunology. 2022;11(5):e1390. doi:10.1002/cti2.1390 Silverberg J, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi:10.1016/j.jaci.2019.08.013 Bağci IS and Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3): P858-866. doi: 10.1016/j.jaci.2017.10.045 Dillon SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [published correction appears in Nat Immunol. 2005;6(1):114.] Nat Immunol. 2004;5(7):752-760. doi: 10.1038/ni1084 Datsi A, et al. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 2021;76:2982-2997. doi: 10.1111/all.14791 NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024 Augustin M, et al. Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol. 2022;7: 102:adv00830. doi: 10.2340/actadv.v102.3932 Durno N, et al. Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany. J Derm Treatment. 2024;35(1). doi: 10.1080/09546634.2024.2417966 Penton H, et al. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials. Dermatol Ther (Heidelb). 2023;13(11):2549-2571. doi: 10.1007/s13555-023-01038-3 Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347. doi:10.1016/j.anai.2018.07.006 Halvorsen J, et al. Suicidal Ideation, Mental Health Problems, and Social Function in Adolescents with Eczema: A Population-Based Study. J Invest Derm. 2014;134: 1847-1854. doi: https://doi.org/10.1038/jid.2014.70 Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 suppl):S115-S123. PMID:28978208 Hahn EL, Bacharier LB. The atopic march: the pattern of allergic disease development in childhood. Immunol Allergy Clin North Am. 2005;25(2):231-246. doi:10.1016/j.iac.2005.02.004 Silverberg J, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 & 2): results from two replicate double-blinded, randomised controlled phase 3 trials. Lancet. 2024. doi: 10.1016/S0140-6736(24)01203-0 Galderma. CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union. Available online . Accessed December 2024 Galderma. Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries. Available online . Accessed December 2024 Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed December 2024 Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed December 2024 ClinicalTrials.Gov . Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03985943). Available online . Accessed December 2024 ClinicalTrials.Gov . Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03989349). Available online . Accessed December 2024 Raharja A, et al. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-173. doi: 10.7861/clinmed.2021-0257 View source version on businesswire.com : https://www.businesswire.com/news/home/20241213562840/en/ CONTACT: For further information: Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 Sébastien Cros Corporate Communications Director sebastien.cros@galderma.com +41 79 529 59 85 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com +41 21 642 76 43 KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: FDA HEALTH CLINICAL TRIALS GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Galderma Copyright Business Wire 2024. PUB: 12/13/2024 05:09 PM/DISC: 12/13/2024 05:10 PM http://www.businesswire.com/news/home/20241213562840/enThe NCC has authorized Exchange Telecommunications Limited's separation from MTN Nigeria Communications Limited Exchange Telecoms was found to have provided insufficient justification for its inability to cover the expenses, according to NCC The business is currently the sole supplier of international call transit from all Nigerian MNO networks to A-Z destinations abroad CHECK OUT: Don't let unemployment hold you back. Start your digital marketing journey today. Legit.ng journalist Zainab Iwayemi has 5-year-experience covering the Economy, Technology, and Capital Market . Due to unpaid interconnect fees, the Nigerian Communications Commission (NCC) has approved the disconnection of Exchange Telecommunications Limited from MTN Nigeria Communications Limited. In a statement released on Friday, Reuben Mouka, director of public affairs made this known. He said that after a careful examination of the application and the debt's conditions, Exchange Telecoms was deemed to have insufficient explanation for its incapacity to pay the costs. PAY ATTENTION: Follow us on Instagram - get the most important news directly in your favourite app! As per the commission, Exchange was permitted to reply to the disconnection application and make its case; nonetheless, its justifications were judged inadequate. Read also Apply: Nigeria Customs releases update on 2025 recruitment, states requirements Section 100 of the Nigerian Communications Act 2003 and the 2012 Guidelines for Procedure for Granting Approval to Disconnect Telecommunications Operators both authorize the disconnection, which will go into effect five days after the notice date. “At the expiration of five days from the date of this notice, MTN will discontinue passing voice and data traffic through Exchange and will, thereafter, utilise alternative channels in interconnecting with other Network Service Providers.” BusinessDay reported that the commission made it clear that until further notice, the disconnection will continue. The company is now the only provider transiting international calls from all Nigerian Mobile Network Operators (MNO) networks to A-Z locations overseas, according to Exchange Telecoms' website. BusinessDay reported that Exchange has the most minutes for each of Nigeria's main MNOs and is also connected to them. MTN will use alternate methods to connect with other Network Service Providers after the two telecom behemoths cut off their services. Read also NECA reacts to Lagos Govt decision to seals 3 manufacturing companies MTN speaks on increasing call, data tariffs Legit.ng reported that MTN Nigeria is advocating for the support of higher telecom rates in reaction to the devaluation of the naira and the high cost of foreign exchange. According to the telecommunication company, there would be no incentives for more investments in the sector unless a new traffic structure is authorised. MTN Nigeria's chief financial officer (CFO), Modupe Kadri, stated this during a panel discussion organised by the Nigeria Economic Summit Group (NESG), The Punch reported. PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy! Source: Legit.ngThe government has vowed to conduct a thorough and impartial investigation into the allegations against the police chief, with a focus on uncovering the truth and holding any wrongdoers accountable. The outcome of this investigation is expected to have far-reaching implications for the police force and the government's ability to maintain public trust and confidence in times of crisis.

Max Verstappen has completed the 'work of public interest' ordered by the FIA after swearing in a televised press conference at the Singapore Grand Prix . The Red Bull star and reigning world champion was penalised by the motorsports governing body after describing his car as 'f***ed' in an arena which restricts drivers from using foul language. FIA boss Mohammed Ben Sulayem decided to tie the community work in with the FIA Awards Ceremony 2024 in Rwanda tonight (Friday). Before heading to the gathering in Kigali, Verstappen attended the grassroots development program of the Rwandan Automobile Club (RAC) - an organisation which seeks to create opportunities for youngsters to enter the world of motorsports. Footage posted to social media shows Verstappen, standing alongside Ben Sulayem, addressing a crowd of people at an outdoor track after watching an activity involving an 'FIA affordable cross car', which was built by the RAC using FIA blueprints. "In the whole world, everything is getting more and more expensive, so the more you can build [motorsports] in your own country, the more you make it affordable for kids," he said . "I think it's great to have that possibility, and I hope it stimulates all these kids so that they want to be a racing driver or an engineer in the future. "It has massive potential and that is what I think everyone is working on trying to make everyone very enthusiastic. It doesn't matter where in the world you come from, anything is possible. Max Verstappen in Rwanda today completing his community service for swearing ?????? (via fia.official/IG) pic.twitter.com/M124sasKCe "That's why I also think it's important that we're here. I'm very excited to see that hopefully, in five to ten years, there are more people coming through [into motorsports]." Verstappen's kind words came two months after he described his unusual punishment - the specifics of which were undisclosed at the time - as 'ridiculous'. The Grand Prix Drivers' Association also wrote an open letter to the FIA asking to be treated like adults. The trip to Rwanda is a celebratory one for Verstappen, who mathematically sealed his fourth consecutive Drivers' Championship two races before the end of the 2024 season. Lando Norris - his nearest challenger - ended up 63 points adrift. A fourth crown catapults Verstappen even further into the upper echelons of F1 greatness. Now level with Sebastian Vettel and Alain Prost, only Juan Manuel Fangio, Lewis Hamilton and Michael Schumacher have enjoyed more world title success than the Dutchman.Jimmy Carter, the farmer, president and Nobel peace crusader, dies at age 100Global Productivity Software Publishing Market Forecast 2024-2033: Analyzing Growth Drivers, Market Share, and Segments

Share Tweet Share Share Email In an era where technology drives innovation and progress, ensuring that our advancements align with environmental sustainability is crucial. The rapid growth of technology has introduced significant benefits, but it has also posed challenges, particularly concerning energy consumption, e-waste, and carbon emissions. At IT Digital Media , we believe that sustainable tech practices are not only necessary but also achievable. This guide explores practical strategies and innovative solutions for creating a greener tech ecosystem. Understanding Sustainable Technology Sustainable technology refers to the use of technology in ways that minimize negative environmental impacts. This includes designing, producing, and using tech products and services that are energy-efficient, recyclable, and responsible. By adopting sustainable practices, businesses and individuals can contribute to a healthier planet while reaping economic and social benefits. The Importance of Sustainable Tech Practices Reducing Carbon Footprint : Technology-related industries are significant contributors to global greenhouse gas emissions. Sustainable practices help reduce this impact. Minimizing E-Waste : Millions of tons of electronic waste end up in landfills annually. Sustainable solutions encourage recycling and reuse. Cost Efficiency : Energy-efficient technologies often result in reduced operational costs for businesses. Corporate Responsibility : Companies adopting green practices enhance their brand reputation and meet increasing consumer demands for eco-friendly solutions. Key Sustainable Tech Practices Here are actionable strategies to adopt sustainable technology practices: 1. Energy-Efficient Data Centers Data centers consume vast amounts of energy to power and cool servers. Transitioning to energy-efficient models is a critical step in sustainability: Green Energy Sources : Utilize renewable energy, such as solar or wind, to power data centers. Virtualization : Consolidate workloads onto fewer servers to reduce energy consumption. Cooling Optimization : Implement advanced cooling systems like liquid cooling or free-air cooling to enhance efficiency. 2. Eco-Friendly Hardware Design Manufacturers and businesses can prioritize environmentally friendly hardware design by: Using Recyclable Materials : Opt for materials that can be recycled or biodegraded. Designing for Durability : Create devices with longer lifespans to reduce frequent replacements. Modular Components : Enable easy upgrades and repairs to minimize electronic waste. 3. Circular Economy in Tech A circular economy focuses on extending the lifecycle of products through repair, reuse, and recycling: E-Waste Recycling Programs : Participate in or establish e-waste collection and recycling initiatives. Refurbished Devices : Encourage the use of refurbished tech products to reduce demand for new manufacturing. Sharing Platforms : Promote tech-sharing platforms where users can borrow rather than buy devices. 4. Sustainable Software Development Software development also has a role to play in sustainability: Energy-Efficient Code : Write optimized code that requires less computational power. Cloud Optimization : Use cloud services that are powered by renewable energy. Green Software Metrics : Measure and reduce the environmental impact of software applications. 5. Smart Technology Integration Smart technologies can significantly improve energy management and resource utilization: Smart Grids : Integrate IoT and AI to optimize energy distribution and consumption. Energy Monitoring Systems : Use sensors and software to track and reduce energy use in offices and homes. Smart Appliances : Invest in appliances that are energy-efficient and IoT-enabled. Real-World Examples of Sustainable Tech Practices Google : Achieved carbon neutrality in 2007 and is committed to running on carbon-free energy by 2030. Apple : Uses 100% renewable energy in its facilities and prioritizes recycled materials in its products. Dell : Offers take-back and recycling programs for used devices. These companies set benchmarks for others to follow, proving that sustainable tech practices are not only feasible but also profitable. The Role of IT Digital Media At IT Digital Media , we’re dedicated to promoting and supporting sustainable tech practices. Through our platform, we: Educate : Provide insights and resources on the latest green technologies and strategies. Inspire : Share success stories of businesses adopting sustainable practices. Connect : Highlight tools and platforms that help organizations and individuals make eco-friendly choices. Explore our resources at https://www.itdigitalmedia.com to stay updated on sustainable innovations in technology. How Individuals Can Contribute Adopting sustainable tech practices isn’t just for businesses; individuals can make a significant impact too: Extend Device Lifespan : Repair and upgrade devices instead of replacing them frequently. Recycle Responsibly : Dispose of electronics at designated e-waste recycling centers. Energy Conservation : Use energy-saving settings on devices and unplug chargers when not in use. Support Green Brands : Choose products from companies committed to sustainability. Challenges in Implementing Sustainable Tech Practices While the benefits of sustainable technology are clear, challenges remain: Initial Costs : Transitioning to green technologies often requires upfront investments. Awareness : Many businesses and individuals lack awareness of sustainable options. Scalability : Implementing large-scale sustainable solutions can be complex. Despite these challenges, the long-term advantages make sustainability an essential pursuit for the tech industry. The Future of Sustainable Technology The future of sustainable technology is promising, driven by innovation and global awareness. Key trends include: Renewable Energy Integration : Greater reliance on solar, wind, and other renewable sources. Advanced Recycling Techniques : Innovations in material recovery and reuse. AI for Sustainability : Using AI to predict and optimize resource utilization. At IT Digital Media, we’re excited to witness and report on these advancements, ensuring our readers are well-equipped to participate in the journey toward a greener future. Sustainability in technology is no longer optional—it’s imperative. By adopting energy-efficient practices, embracing a circular economy, and leveraging smart technologies, we can build a tech ecosystem that supports both innovation and the environment. Whether you’re a business leader or a tech enthusiast, there’s a role for everyone in this movement Related Items: Eco-friendly , Sustainability , Sustainable technology Share Tweet Share Share Email Recommended for you Sustainable Tech: How Can Businesses Contribute to a Greener Future? Eco-Friendly Excellence: 2024 Green Cleaning Solutions for Commercial Spaces Leveraging Weather Data to Improve Emergency Response Comments

The initial diagnosis revealed that Sun had sustained a serious head injury, including a concussion and brain trauma. The extent of the damage is still being assessed, but the injury has raised alarm bells within the basketball community and prompted calls for better protection of players from deliberate acts of violence on the court.

Atalanta can win the Serie A title, years of experience help Atalanta players adapt to pressureEmbarking on an adventurous journey, composing an epic hero's saga: Three Samsung Monitors and "The Lion King: Legend of Mufasa" set off on a royal adventure

What sets Sun Yingsha apart from her peers is not just her remarkable talent on the table, but also her unique sense of style and grace off the court. With her striking looks and impeccable fashion sense, she has captured the attention of the fashion world and has become a style icon in her own right. Her appearance on the cover of ELLE magazine's New Year issue is a testament to her growing influence in the fashion industry.

Woman who falsely accused Duke lacrosse players of rape in 2006 publicly admits she liedWalmart's best weekend deals: Major price drops on Skechers, HP, Shark and more

Trump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’As the realization of her situation sank in, Mrs. Chen's emotions overflowed, and tears streamed down her wrinkled cheeks. She was grateful for the kindness and assistance of Mr. Li and the police officers who had come to her aid. In her moment of vulnerability, she found solace in the compassion of strangers who had shown her empathy and support.

As OpenAI continues to push the boundaries of AI research and innovation, Sora stands as a testament to the organization's commitment to excellence and its dedication to advancing the field of artificial intelligence. The future of video generation has arrived, and it looks brighter than ever with the introduction of Sora.In recent news, leading technology company NVIDIA has made a public statement expressing its readiness to answer any regulatory inquiries and showcase a cooperative spirit towards regulatory authorities. This development comes amidst increasing scrutiny on tech companies regarding competition practices, data privacy, and security concerns, reflecting a growing trend towards greater accountability within the industry.

Rokmaster Resources Corp. ( CVE:RKR – Get Free Report ) fell 25% during trading on Friday . The company traded as low as C$0.02 and last traded at C$0.02. 396,000 shares traded hands during mid-day trading, an increase of 182% from the average session volume of 140,187 shares. The stock had previously closed at C$0.02. Rokmaster Resources Trading Down 25.0 % The firm has a market capitalization of C$2.45 million, a price-to-earnings ratio of -0.30 and a beta of 2.99. The company has a quick ratio of 0.60, a current ratio of 0.02 and a debt-to-equity ratio of 103.54. The firm’s 50 day moving average is C$0.02 and its 200 day moving average is C$0.02. Rokmaster Resources Company Profile ( Get Free Report ) Rokmaster Resources Corp., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in North, Central, and South America. It explores for zinc, lead, silver, copper, gold, and polymetallic deposits, as well as precious metals. The company holds a 100% in the Duncan Lake property comprising 35 contiguous mineral claims that covers an area of 3,929 hectares; and a 55% interest in the Big Copper property located in the Slocan Mining Division in southeast British Columbia, Canada. See Also Receive News & Ratings for Rokmaster Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rokmaster Resources and related companies with MarketBeat.com's FREE daily email newsletter .

Trump's latest statements are likely to reignite these debates and further polarize public opinion on immigration. Supporters of his hardline policies may see his calls for the expulsion of undocumented immigrants as a necessary step to protect American sovereignty and secure the country's borders. On the other hand, opponents are likely to view this as a heartless and impractical approach that ignores the complexities of the immigration system and the contributions that immigrants make to American society.

BOSTON , Dec. 13, 2024 /PRNewswire/ -- The China Fund, Inc. (NYSE: CHN) (the "Fund") announced today that the Fund's annual stockholder meeting (the "Meeting") will be scheduled for Thursday, March 13, 2025 , via a virtual forum at 11:00 a.m. ET . Stockholders of record as of January 15, 2025 will be entitled to notice of, and to attend and vote at, the Meeting. The notice for the Meeting will be mailed to shareholders on or about February 10, 2025 . The Fund is a closed-end management investment company with the objective of seeking long-term capital appreciation by investing primarily in equity securities (i) of companies for which the principal securities trading market is in the People's Republic of China (" China "), or (ii) of companies for which the principal securities trading market is outside of China , or constituting direct equity investments in companies organized outside of China , that in both cases derive at least 50% of their revenues from goods and services sold or produced, or have at least 50% of their assets, in China . While the Fund is permitted to invest in direct equity investments of companies organized in China , it presently holds no such investments. Shares of the Fund are listed on the New York Stock Exchange under the ticker symbol "CHN". The Fund's investment manager is Matthews International Capital Management, LLC. For further information regarding the Fund and the Fund's holdings, please call (888)-CHN-CALL (246-2255) or visit the Fund's website at www.chinafundinc.com . View original content: https://www.prnewswire.com/news-releases/the-china-fund-inc-announces-date-of-annual-meeting-of-stockholders-302331705.html SOURCE The China Fund, Inc.AP News Summary at 4:47 p.m. ESTThe outcome of the investigation into NVIDIA remains uncertain, but the case serves as a reminder to companies operating in China and other jurisdictions to stay vigilant about compliance with anti-monopoly laws. The tech industry, in particular, is facing increased scrutiny from regulators worldwide, as concerns about market concentration, pricing practices, and consumer welfare continue to dominate the regulatory landscape.

As tensions within the alliance continue to simmer, it is clear that the issue of defense spending and burden-sharing will remain a contentious and divisive issue for NATO members. The rift between the United States and its allies over financial contributions threatens to undermine the unity and solidarity of the alliance, potentially weakening NATO's ability to effectively deter threats and respond to security challenges in an increasingly uncertain world.One of the highly anticipated films set to premiere during the Spring Festival is a high-octane action thriller, "The Dragon's Fury." Starring A-list action stars, this adrenaline-pumping film promises to deliver non-stop excitement and jaw-dropping stunts that will leave audiences on the edge of their seats. With a gripping plot and spectacular special effects, "The Dragon's Fury" is poised to be a box office hit during the holiday season.